Jpmorgan Chase & CO Akebia Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 741,161 shares of AKBA stock, worth $2.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
741,161
Previous 456,294 62.43%
Holding current value
$2.04 Million
Previous $848,000 67.81%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$1.69 - $2.84 $481,425 - $809,022
284,867 Added 62.43%
741,161 $1.42 Million
Q4 2024

Feb 12, 2025
BUY
$1.26 - $2.13 $450,762 - $762,003
357,748 Added 363.03%
456,294 $848,000
Q3 2024

Dec 26, 2024
BUY
$0.94 - $1.55 $9,082 - $14,976
9,662 Added 10.87%
98,546 $130,000
Q3 2024

Nov 08, 2024
BUY
$0.94 - $1.55 $9,082 - $14,976
9,662 Added 10.87%
98,546 $130,000
Q2 2024

Dec 26, 2024
SELL
$0.86 - $1.63 $8,309 - $15,749
-9,662 Reduced 9.8%
88,884 $90,000
Q2 2024

Aug 12, 2024
BUY
$0.86 - $1.63 $76,241 - $144,504
88,653 Added 38377.92%
88,884 $90,000
Q1 2024

Dec 26, 2024
SELL
$1.27 - $2.24 $124,860 - $220,225
-98,315 Reduced 99.77%
231 $0
Q4 2023

Dec 26, 2024
SELL
$0.8 - $1.28 $78,652 - $125,843
-98,315 Reduced 99.77%
231 $0
Q4 2023

Feb 12, 2024
SELL
$0.8 - $1.28 $75,694 - $121,111
-94,618 Reduced 99.76%
231 $0
Q3 2023

Nov 14, 2023
BUY
$0.87 - $1.84 $49,543 - $104,780
56,946 Added 150.24%
94,849 $108,000
Q2 2023

Aug 11, 2023
SELL
$0.51 - $1.43 $22,258 - $62,410
-43,644 Reduced 53.52%
37,903 $34,000
Q1 2023

May 11, 2023
BUY
$0.56 - $1.15 $43,401 - $89,128
77,503 Added 1916.49%
81,547 $45,000
Q4 2022

Feb 13, 2023
SELL
$0.25 - $0.58 $1,836 - $4,261
-7,347 Reduced 64.5%
4,044 $2,000
Q3 2022

Nov 14, 2022
BUY
$0.3 - $0.46 $1,251 - $1,918
4,171 Added 57.77%
11,391 $4,000
Q2 2022

Aug 11, 2022
SELL
$0.32 - $0.67 $1.36 Million - $2.85 Million
-4,250,978 Reduced 99.83%
7,220 $3,000
Q1 2022

May 11, 2022
SELL
$0.72 - $2.93 $125,283 - $509,834
-174,005 Reduced 3.93%
4,258,198 $3.06 Million
Q4 2021

Feb 10, 2022
SELL
$2.26 - $3.34 $301,782 - $445,996
-133,532 Reduced 2.92%
4,432,203 $10 Million
Q3 2021

Nov 12, 2021
BUY
$2.35 - $3.88 $10.7 Million - $17.7 Million
4,565,735 New
4,565,735 $13.2 Million

Others Institutions Holding AKBA

# of Institutions
170
Shares Held
106M
Call Options Held
134K
Put Options Held
262K
View Full List

About Akebia Therapeutics, Inc.

AKBA Quotes by TradingView
  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $506M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email